Superbug antibiotic Zaynich, cancer drug Daraxonrasib: 2 medical marvels in 1 week

While the world focuses on diseases like Covid, Ebola, and Hantavirus, another threat has been silently growing even larger: Antimicrobial Resistance (AMR). Drug-resistant bacteria are making infections harder to treat and putting decades of medical progress at risk. In this episode The Brief, we explore the groundbreaking approval of Zaynich, a novel antibiotic developed by Indian pharmaceutical company Wockhardt and recently approved by the US FDA. The drug is being hailed as a major breakthrough in the fight against multidrug-resistant bacteria and marks the first New Chemical Entity fully discovered, developed, and commercialized by an Indian company to receive FDA approval. We also examine another remarkable medical breakthrough: Daraxonrasib, an experimental drug showing promising results against pancreatic cancer, one of the deadliest and most difficult cancers to treat. After decades of research targeting the elusive KRAS mutation, scientists may finally have a new weapon in the fight against this devastating disease. From superbugs to cancer research, this is the story of how committed scientists continue to push the boundaries of what once seemed impossible.